trial · primary record
Drug 1: LY3023414; Drug 2: Prexasertib
Triple Negative Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 10 |
| Primary completion | 2022-11-26 |
| Primary endpoint | Efficacy (Objective Response Rate) |
| Registry ID | NCT04032080 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:12.842Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04032080
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.